Compare FRBA & EOLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FRBA | EOLS |
|---|---|---|
| Founded | 2007 | 2012 |
| Country | United States | United States |
| Employees | 336 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 414.6M | 454.4M |
| IPO Year | N/A | 2018 |
| Metric | FRBA | EOLS |
|---|---|---|
| Price | $17.26 | $6.85 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $17.50 | $15.50 |
| AVG Volume (30 Days) | 114.2K | ★ 758.9K |
| Earning Date | 04-27-2026 | 05-04-2026 |
| Dividend Yield | ★ 2.40% | N/A |
| EPS Growth | N/A | ★ 1.23 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $297,176,000.00 |
| Revenue This Year | $14.68 | $13.27 |
| Revenue Next Year | $6.08 | $17.62 |
| P/E Ratio | $9.71 | ★ N/A |
| Revenue Growth | N/A | ★ 11.61 |
| 52 Week Low | $14.41 | $3.86 |
| 52 Week High | $18.19 | $10.20 |
| Indicator | FRBA | EOLS |
|---|---|---|
| Relative Strength Index (RSI) | 57.67 | 53.68 |
| Support Level | $14.71 | $6.44 |
| Resistance Level | $17.46 | $6.95 |
| Average True Range (ATR) | 0.46 | 0.31 |
| MACD | -0.02 | -0.04 |
| Stochastic Oscillator | 51.85 | 46.67 |
First Bank is a full-service commercial bank, with target businesses from individuals, businesses, and governmental entities located in service regions throughout New Jersey and eastern Pennsylvania, with a particular focus between New York City and Philadelphia. The group focuses on traditional deposit and loan products with businesses and individuals living and working in markets as the source of business. Its services are Business Banking, Personal Banking, Digital Banking, and Lending.
Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.